 In June 2012, a new drug candidate named "Rhosin" was synthesized by researchers at the Cincinnati Children's Hospital, a drug with the full intention to inhibit cancer proliferation and promote nerve cell regeneration.This inhibitor specifically targets Rho GTPases to prevent cell growth related to cancer.When tested on breast cancer cells, Rhosin inhibited growth and the growth of mammary spheres in a dose dependent manner, functioning as targets for RhoA while simultaneously maintaining the integrity of normal cellular processes and normal breast cells.